Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Virginia D. Steen¹ and Robyn T. Domsic², ¹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ²Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…
Abstract Number: 2576 • 2013 ACR/ARHP Annual Meeting
Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Adrienne M. Roos¹, Christopher Pasarikovski¹, Amie T. Kron¹, John T. Granton², Peter Lee³, John Thenganatt⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Divisions of Respirology and Critical Care Medicine, Toronto, ON, Canada, ⁵Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Epoprostenol has been demonstrated to improve hemodynamics, functional class, and six-minute walk distance (6MWD) in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH…
Abstract Number: 2577 • 2013 ACR/ARHP Annual Meeting
Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
Christopher Pasarikovski¹, John T. Granton², Peter Lee³, Adrienne M. Roos¹, Amie T. Kron¹, Cathy Chau⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and idiopathic PAH (IPAH) are conditions with poor survival. There is evidence to suggest that sex…
Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Hebah Alhajeri¹, Marie Hudson², Marvin J. Fritzler³, Janet E. Pope⁴, Canadian Scleroderma Research Group -⁵ and Murray Baron⁶, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴St Joseph Health Care, London, ON, Canada, ⁵Jewish General Hospital, Montreal, QC, Canada, ⁶Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…
Abstract Number: 1811 • 2013 ACR/ARHP Annual Meeting
Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
Aaliya Yaqub¹, Lorinda Chung², David Fiorentino³ and Eswar Krishnan⁴, ¹Stanford Univ Medical Center, Stanford, CA, ²Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease associated with substantial morbidity. Epidemiologic studies using large administrative databases often rely on the accuracy of…
Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting
Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Svetlana I. Nihtyanova¹, Benjamin E. Schreiber², Voon H. Ong³, John G. Coghlan⁴, Athol U. Wells⁵ and Christopher P. Denton⁶, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ³Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ⁴National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, ⁵Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁶Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…
Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Elana J. Bernstein¹, Jessica K. Gordon², Wei-Ti Huang³ and Virginia D. Steen⁴, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Yun Zhang, Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…
Abstract Number: 688 • 2013 ACR/ARHP Annual Meeting
Minimal Clinically Important Investigations In Systemic Sclerosis
Jessica Meijs¹, Anne A. Schouffoer¹, Nina Ajmone Marsan², Maarten K. Ninaber³ and Tom W.J. Huizinga¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Cardiology, Leiden University Medical Center, Leiden, Netherlands, ³Pulmonology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The optimal management of Systemic Sclerosis (SSc) is a challenge due to the complexity of early diagnosis and identification of patients who are at…
Abstract Number: 710 • 2012 ACR/ARHP Annual Meeting
Optical Density Measure of the Papillary Dermis Discriminates As Abnormal Clinically Uninvolved Skin in Systemic Sclerosis and Correlates with Severity of Skin Thickness
Giuseppina Abignano¹, Sibel Z. Aydin², Concepcion Castillo-Gallego³, Daniel Woods⁴, Adam Meekings⁵, Dennis McGonagle⁶, Paul Emery⁷ and Francesco Del Galdo⁸, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Unit of Rheumatology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Michelson Diagnostics Ltd, Kent, United Kingdom, ⁵Michelson Diagnostics Ltd, Kent, United Kingdom, Kent, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁸Musculoskeletal Diseases, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Skin involvement in systemic sclerosis (SSc) is often primary outcome in clinical trials and its severity inversely correlates with prognosis. Nevertheless, an objective quantitative…
Abstract Number: 92 • 2012 ACR/ARHP Annual Meeting
Combined Response Index in Diffuse Systemic Sclerosis (CRISS)—Which External Anchors to Use When Developing the Index? Baseline Analysis
Dinesh Khanna¹, Veronica Berrocal², James R. Seibold³, Peter A. Merkel⁴, Maureen D. Mayes⁵, Kristine Phillips⁶, Robert W. Simms⁷, Shervin Assassi⁵, Philip J. Clements⁸ and Daniel Furst⁹, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Scleroderma Research Consultants LLC, Avon, CT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁶Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, Boston University School of Medicine, Boston, MA, ⁸University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁹Div of Rheumatology, UCLA Medical School, Los Angeles, CA
Background/Purpose: As part of an NIH sponsored effort to develop a data-driven CRISS, we evaluated the face, content, and construct validity (convergent and discriminant) of…
Abstract Number: L3 • 2012 ACR/ARHP Annual Meeting
Classification Criteria for Systemic Sclerosis: Preliminary Results
Janet E. Pope¹, Dinesh Khanna², Jaap Fransen³, Sindhu R. Johnson⁴, Murray Baron⁵, Alan G. Tyndall⁶, Marco Matucci-Cerinic⁷, Raymond P. Naden⁸, Frank H.J. van den Hoogen⁹ and ACR/EULAR Classification Criteria for Systemic Sclerosis¹⁰, ¹Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, ⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁶Rheumatology, University of Basel, Basel, Switzerland, ⁷Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, ⁸Auckland City Hospital, Auckland, New Zealand, Austria, ⁹Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ¹⁰Janet Pope, London, ON, Canada
Background/Purpose: The existing 1980 classification criteria for systemic sclerosis (SSc) are suboptimal for patients with early SSc and some patients with limited cutaneous SSc (lcSSc)…
Abstract Number: 2422 • 2012 ACR/ARHP Annual Meeting
Sexual Activity and Sexual Functioning Among Women with Systemic Sclerosis Compared to Women From a Population Sample
Brooke Levis¹, Andrea Burri², Marie Hudson³, Murray Baron⁴ and Brett D. Thombs⁵, ¹Epidemiology, McGill University, Montreal, QC, Canada, ²Twin Research and Genetic Epidemiology, King's College, London, United Kingdom, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁵Psychiatry, McGill University, Montreal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a chronic, multi-system, connective tissue disorder characterized by thickening and fibrosis of the skin and internal organ involvement.…
Abstract Number: 2303 • 2012 ACR/ARHP Annual Meeting
Confirmation of TNIP1 As a Susceptibility Locus for Systemic Sclerosis in a Large Multicentre Study
Lara Bossini-Castillo¹, Jose Ezequiel Martin², Carmen Pilar Simeon³, Lorenzo Beretta⁴, Olga Y. Gorlova⁵, Madelon C. Vonk⁶, Patricia Carreira⁷, the Spanish Scleroderma Group⁸, Annemie Schuerwegh⁹, Alexandre Voskuyl¹⁰, Anna-Maria Hoffmann-Vold¹¹, Roger Hesselstrand¹², Annika Nordin¹³, Claudio Lunardi¹⁴, Jaap Van Laar¹⁵, Paul Shiels¹⁶, Ariane Herrick¹⁷, Jane Worthington¹⁸, Carmen Fonseca¹⁹, Christopher P. Denton¹⁹, Shervin Assassi²⁰, Bobby P.C. Koeleman²¹, Maureen D. Mayes²², T.R.D.J. Radstake²³ and Javier Martin¹, ¹Immunology, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, ²Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ³Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain, ⁴Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁵Department of Epidemiology, UT M. D. Anderson Cancer Center, Houston, TX, ⁶Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Granada, Spain, ⁹Leids Univ Medisch Centrum, Leiden, Netherlands, ¹⁰Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹¹Rheumatology, Oslo University Hospital, Oslo, Norway, ¹²Rheumatology, Lund University, Lund, Sweden, ¹³Department of Rheumatology, Karolinska Institute, Stockholm, Sweden, ¹⁴Department of Medicine, Università degli Studi di Verona, Verona, Italy, ¹⁵Rheumatology, Leiden University Hospital, Leiden, Netherlands, ¹⁶University of Glasgow, Glasgow, United Kingdom, ¹⁷Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom, ¹⁸Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ¹⁹Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²⁰Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²¹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ²²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic sclerosis or scleroderma (SSc) is a complex autoimmune disorder that affects the connective tissue causing fibrosis in the skin and different internal organs.…
Abstract Number: 2295 • 2012 ACR/ARHP Annual Meeting
Caveolin-1 Deficiency Induces Spontaneous Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells in Vitro
Zhaodong Li¹, Peter J. Wermuth², Bryan Benn², Michael P. Lisanti³ and Sergio A. Jimenez², ¹Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA, ²Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, ³Jefferson Stem Cell Biology and Regenerative Medicine Center, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Recent studies demonstrated that the phenotypic transition of endothelial cells (EC) into activated mesenchymal cells, a process known an endothelial-to-mesenchymal transition (EndoMT), may be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.